Clinical impact of MUC1 and MUC4 expression in Barrett-associated oesophageal adenocarcinoma

Journal of Clinical Pathology

Volumn 62, Issue 12, 2009, Pages 1144-1146

  Piessen, Guillaume ^a   Wacrenier, A ^b   Briez, N ^a   Triboulet, J P ^a   Van Seuningen, I ^a   Mariette, C ^a  

^a JEAN PIERRE AUBERT RESEARCH CENTER   (France)

^b UNIV LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

MUCIN 1; MUCIN 4;

ARTICLE; BARRETT ESOPHAGUS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ASSOCIATION; DYSPLASIA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS MUCOSA; ESOPHAGUS RESECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; METAPLASIA; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADENOCARCINOMA; BARRETT ESOPHAGUS; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FOLLOW-UP STUDIES; HUMANS; MUCIN-1; MUCIN-4; NEOPLASM PROTEINS; PRECANCEROUS CONDITIONS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 73449134858     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jcp.2008.060780     Document Type: Article

References (13)

1. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol 2007;8:545-53.
2. Hollingsworth MA, Swanson BJ. Mucins in cancer: protection and control of the cell surface. Nat Rev Cancer 2004;4:45-60.
3. Piessen G, Jonckheere N, Vincent A, et al. Regulation of the human mucin MUC4 by taurodeoxycholic and taurochenodeoxycholic bile acids in oesophageal cancer cells is mediated by hepatocyte nuclear factor 1alpha. Biochem J 2007;402:81-91.
4. Mariette C, Piessen G, Leteurtre E, et al. Activation of MUC1 mucin expression by bile acids in human esophageal adenocarcinomatous cells and tissues is mediated by the phosphatidylinositol 3-kinase signaling pathway. Surgery 2008;143:58-71.
5. Chinyama CN, Marshall RE, Owen WJ, et al. Expression of MUC1 and MUC2 mucin gene products in Barrett's metaplasia, dysplasia and adenocarcinoma: an immunopathological study with clinical correlation. Histopathology 1999;35:517-24.
6. Piessen G,Mariette C, Van Seuningen I.Mucin expression and regulation in oesophageal cancer: New molecular targets in cancer progression from Barrett's oesophagus to adenocarcinoma? In: Van Seuningen I, ed. The epithelial mucins: structure/function. Roles in cancer and inflammatory diseases. Kerala: Research Signpost, 2008:169-81.
7. Bax DA, Einerhand AWC, van Dekken H, et al. MUC4 is increased in high grade intraepithelial neoplasia in Barrett's oesophagus and is associated with a proapoptotic Bax to Bcl-2 ratio. J Clin Pathol 2004;57:1267-72.
8. van der Vegt B, de Roos MA, Peterse JL, et al. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. Histopathology 2007;51:322-35.
9. Saitou M, Goto M, Horinouchi M, et al. MUC4 expression is a novel prognostic factor in patients with invasive ductal carcinoma of the pancreas. J Clin Pathol 2005;58:845-52.
10. Flucke U, Steinborn E, Dries V, et al. Immunoreactivity of cytokeratins (CK7, CK20) and mucin peptide core antigens (MUC1, MUC2, MUC5AC) in adenocarcinomas, normal and metaplastic tissues of the distal oesophagus, oesophago-gastric junction and proximal stomach. Histopathology 2003;43:127-34.
11. Glickman JN, Blount PL, Sanchez CA, et al. Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus. Hum Pathol 2006;37:1304-15.
12. Gulmann C, Counihan I, Grace A, et al. Cytokeratin 7/20 and mucin expression patterns in oesophageal, cardia and distal gastric adenocarcinomas. Histopathology 2003;43:453-61.
13. Wang RQ, Fang DC. Alterations of MUC1 and MUC3 expression in gastric carcinoma: relevance to patient clinicopathological features. J Clin Pathol 2003;56:378-84.